Literature DB >> 22520531

Safety and efficacy of rescue angioplasty for ST-elevation myocardial infarction with high utilization rates of glycoprotein IIb/IIIa inhibitors.

Ibrahim M Shugman1, Victar Hsieh, Samuel Cheng, Devang Parikh, Daniel Tobing, Noemi Wouters, Rozemarijn van der Vijver, Queenie Lo, Rohan Rajaratnam, Andrew P Hopkins, Sidney Lo, Dominic Leung, Craig P Juergens, John K French.   

Abstract

BACKGROUND: Fibrinolytic therapies remain widely used for ST-elevation myocardial infarction, and for "failed reperfusion," rescue percutaneous coronary intervention (PCI) is guideline recommended to improve outcomes. However, these recommendations are based on data from an earlier era of pharmacotherapy and procedural techniques. METHODS AND
RESULTS: To determine factors affecting prognosis after rescue PCI, we studied 241 consecutive patients (median age 55 years, interquartile range [IQR] 48-65) undergoing procedures between 2001 and 2009 (53% anterior ST-elevation myocardial infarction and 78% transferred). The median treatment-related times were 1.2 hours (IQR 0.8-2.2) from symptom onset to door, 2 hours (IQR 1.3-3.2) from symptom onset to fibrinolysis (93% tenecteplase), and 3.9 hours (IQR 3.1-5.2) from fibrinolysis to balloon. Procedural characteristics were stent deployment in 95% (11.6% drug eluting) and 78% glycoprotein IIb/IIIa inhibitor use, and Thrombolysis In Myocardial Infarction (TIMI) 3 flow rates pre-PCI and post-PCI were 41% and 91%, respectively (P < .001). At 30 days, TIMI major bleeding occurred in 16 (6.6%) patients, and 23 (9.5%) patients received transfusions; nonfatal stroke occurred in 4 (1.7%) patients (2 hemorrhagic). Predictors of TIMI major bleeding were female gender (odds ratio 3.194, 95% CI 1.063-9.597; P = .039) and pre-PCI shock (odds ratio 3.619, 95% CI,1.073-12.207; P = .038). Mortality at 30 days was 6.2%, and 3.2% in patients without pre-PCI shock. One-year mortality was 8.2% (5.3% in patients without pre-PCI cardiogenic shock), 5.2% had reinfarction, and the target vessel revascularization rate was 6.4% (2.6% in arteries ≥ 3.5 mm in diameter). Pre-PCI shock, female gender, and post-PCI TIMI flow grades ≤ 2 were significant predictors of 1-year mortality on multivariable regression modeling, but TIMI major bleeding was not.
CONCLUSIONS: Rescue PCI with contemporary treatments can achieve mortality rates similar to rates for contemporary primary PCI in patients without pre-PCI shock. Whether rates of bleeding can be reduced by different pharmacotherapies and interventional techniques needs clarification in future studies.
Copyright © 2012 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22520531     DOI: 10.1016/j.ahj.2012.01.014

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Is There Still a Role for Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes?

Authors:  Loredana Iannetta; Paolo Emilio Puddu; Domenico Cuturello; Angela Saladini; Mariano Pellicano; Michele Schiariti
Journal:  Cardiol Res       Date:  2013-03-08

2.  Cost-effectiveness of a European ST-segment elevation myocardial infarction network: results from the Catalan Codi Infart network.

Authors:  Ander Regueiro; Julia Bosch; Victoria Martín-Yuste; Alba Rosas; Maria Teresa Faixedas; Joan Antoni Gómez-Hospital; Jaume Figueras; Antoni Curós; Angel Cequier; Javier Goicolea; Antonio Fernández-Ortiz; Carlos Macaya; Ricard Tresserras; Laura Pellisé; Manel Sabaté
Journal:  BMJ Open       Date:  2015-12-09       Impact factor: 2.692

3.  Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.

Authors:  José M De la Torre Hernández; Mario Sadaba Sagredo; Miren Telleria Arrieta; Federico Gimeno de Carlos; Elena Sanchez Lacuesta; Juan A Bullones Ramírez; Javier Pineda Rocamora; Victoria Martin Yuste; Tamara Garcia Camarero; Mariano Larman; Jose R Rumoroso
Journal:  BMC Cardiovasc Disord       Date:  2017-08-01       Impact factor: 2.298

4.  Reperfusion After Fibrinolytic Therapy (RAFT): An open-label, multi-centre, randomised controlled trial of bivalirudin versus heparin in rescue percutaneous coronary intervention.

Authors:  Amir Faour; Nicholas Collins; Trent Williams; Arshad Khan; Craig P Juergens; Sidney Lo; Darren L Walters; Derek P Chew; John K French
Journal:  PLoS One       Date:  2021-10-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.